Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Bolsa de Madrid  >  Grifols SA       ES0171996012

GRIFOLS SA
Mes dernières consult.
Most popular
Report
 SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials (€)
Sales 2017 4 330 M
EBIT 2017 1 109 M
Net income 2017 635 M
Debt 2017 5 596 M
Yield 2017 1,48%
Sales 2018 4 528 M
EBIT 2018 1 207 M
Net income 2018 723 M
Debt 2018 5 201 M
Yield 2018 1,68%
P/E ratio 2017 26,11
P/E ratio 2018 22,83
EV / Sales2017 4,77x
EV / Sales2018 4,48x
Capitalization 15 063 M
More Financials
Company
Grifols SA is a vertically integrated global producer of plasma derivatives.Its activities include sourcing raw material, manufacturing various plasma derivative products and selling and distributing final products to healthcare providers.The company operates through the following segments: ... 
Sector
Pharmaceuticals
Calendar
11/02Earnings Release
More about the company
Surperformance© ratings of Grifols SA
Trading Rating : Investor Rating :
More Ratings
Latest news on GRIFOLS SA
10/09 THE LATEST : Barcelona mayor says all sides must de-escalate
09/26 GRIFOLS : FDA approves Grifols Prolastin-C Liquid for the treatment of alpha-1 a..
09/25 GRIFOLS : research lines in Alzheimer's move forward with both treatment and pre..
09/23 GRIFOLS : Engagement
09/21 GRIFOLS : research lines in Alzheimer's move forward with both treatment and pre..
09/19 GRIFOLS : Select American Red Cross Blood Donations Screened for Babesia Parasit..
09/03 GRIFOLS : Value Based Pharmaceutical Pricing – Is it Affordable?
09/02 GRIFOLS : Federal Contracts Awarded by Federal Agencies in Kentucky (Sept. 2)
08/31 GRIFOLS : MILITARY $42,083 Federal Contract Awarded to Gen-Probe
08/23 GRIFOLS : Supervisor Solis Commends LA BioStart Graduates at Cal State LA Event
More news
Sector news : Biopharmaceuticals
07:50aDJNOVARTIS : 3Q Net Profit Rises as New Drugs Offset Generic Competition
10/23 European stocks hold firm as banks, Spanish shares fall
10/23 Smith & Nephew to buy Rotation Medical for up to $210 million
10/23DJEuropean Corporate Roundup for Monday
10/23DJDrug Makers Find 'Branded Generics' Are a Source for Growth
More sector news : Biopharmaceuticals
News from SeekingAlpha
2016 Midday Gainers / Losers
2015 Tracking John Paulson's Paulson & Company Portfolio - Q3 2015 Update
2015 TiGenix Achieves First Ever Success In Allogeneic Stem Cell Phase 3 Trial
2015 Tracking John Paulson's Paulson & Company Portfolio - Q2 2015 Update
2015 Tracking John Paulson's Paulson & Company Portfolio - Q1 2015 Update
Income Statement Evolution
Consensus
 
Mean consensus HOLD
Number of Analysts 21
Average target price 24,6 €
Spread / Average Target 1,9%
EPS Revisions
Managers
NameTitle
Raimon Grifols Roura Joint Chief Executive Officer & Director
Victor Grifols Deu Joint Chief Executive Officer & Executive Director
Víctor Grifols Roura Non-Executive Chairman
Alfredo Arroyo Guerra Chief Financial Officer & Vice President
Vicente Blanquer Torre Vice President-Quality, Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
GRIFOLS SA17 705
BIOGEN29.37%71 485
CSL LIMITED39.35%49 894
ALEXION PHARMACEUTICALS13.62%31 027
GRIFOLS SA28.79%17 818
BIOMARIN PHARMACEUTICAL5.93%15 380